Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant irinotecan plus 5-fluorouracil/folinic acid versus 5-fluorouracil/folinic acid in resected colon cancer
ACTRN12610000148077Phase 3Completed
- Sponsor
- HeCOG
- Start
- Jan 1999
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colon cancer comparing irinotecan + folinic acid + 5-fluorouracil with folinic acid + 5-fluorouracil (2 arms). Primary endpoint: Disease-free survival. Started Jan 1999; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on ACTRN12610000148077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000148077.